Showing recent highlights
What's New
ScienceDaily · November 3, 2026
Scientists found that a drug originally created for spinal cord injuries may also help with Alzheimer's disease by repairing damage to DNA inside brain cells and calming brain inflammation — two things that are thought to drive the disease. Because this drug has already been tested in people for safety in a different condition, researchers may be able to move more quickly toward larger studies in people with Alzheimer's. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a brain scan measurement called the ERICA score — which looks at shrinkage in a small but important part of the brain called the entorhinal cortex (one of the first areas damaged in Alzheimer's disease) — can help doctors tell apart different stages of Alzheimer's, from very early memory concerns all the way to a full dementia diagnosis. The ERICA score was especially good at correctly identifying who does *not* have Alzheimer's, and different doctors reading the same scans tended to agree on the results, which suggests it could be a reliable tool in real clinical settings. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that using virtual reality (VR) headsets to guide people with Alzheimer's through group therapy sessions — where they revisited meaningful memories together — led to noticeable improvements in agitation, mood, thinking skills, and social connection compared to those who received only routine care. In plain terms, participants who used the VR sessions seemed calmer, less depressed, and more mentally engaged after eight weeks, and most people tolerated the technology well with only minor side effects like eye fatigue. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that people with mild dementia — including Alzheimer's disease — who listened to personalized music through an AI-driven app for 30 minutes a day over 12 weeks felt noticeably less anxious and less depressed compared to those who didn't use it. In fact, 80% of the music group showed reduced anxiety, versus only 30% in the group that didn't use the app. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a type of exercise called 'dual-task training' — where people do a physical activity and a mental activity at the same time, like walking while answering questions — showed the strongest results for improving thinking and memory skills in people with mild to moderate Alzheimer's disease. A brain stimulation technique called transcranial direct current stimulation (tDCS), which uses gentle electrical currents applied to the scalp to gently activate certain areas of the brain, also ranked highly. These findings suggest that non-drug approaches may offer meaningful cognitive benefits alongside standard care, which could be encouraging news for patients and families looking for additional ways to support brain health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a medication called brexpiprazole helped reduce agitation — things like restlessness, verbal outbursts, or aggressive behavior — in people with Alzheimer's disease, whether or not they were already taking an antidepressant. Interestingly, the benefit appeared even stronger in those who were also on an antidepressant, though falls were reported in a small number of that group and are worth knowing about. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a simple physical test — called the Timed Up and Go test, which measures how long it takes a person to stand up from a chair, walk a short distance, and sit back down — may be linked to Alzheimer's disease and early memory problems. People with Alzheimer's took significantly longer to complete the test compared to those without the condition, and the connection was even stronger when the test was done while the person was also doing a mental task at the same time, like counting. This suggests that how someone moves and balances could reflect what's happening in the brain, which might one day help doctors spot cognitive problems earlier. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · November 1, 2026
Researchers found that PARO — a soft, seal-shaped therapeutic robot designed to provide comfort and companionship — helped reduce agitation, anxiety, and depression in people with dementia living in Australian healthcare settings. Across six studies involving over 1,400 participants, interacting with the robot appeared to ease some of the difficult emotional and behavioral symptoms that often come with Alzheimer's disease and other forms of dementia, which can be hard to manage and deeply affect quality of life. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Guideline Reviews) · November 1, 2026
Researchers found that Ginkgo biloba, a plant-based supplement sometimes used alongside standard treatments for memory and brain conditions, may work better for people with cognitive problems — meaning difficulty with thinking and memory — when taken at higher doses of 240 mg per day or more, based on a review of 29 studies. For someone with Alzheimer's disease, this is interesting because it suggests that the amount taken might matter quite a lot, though scientists also noted that the supplement's ingredients and quality can vary widely between products. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · October 29, 2026
A study of more than 87,000 adults found that people who got more bright daylight each day had a 16% lower chance of developing dementia, and those who got less than 42 minutes of bright daylight daily were at even greater risk — more so than people with six well-known dementia risk factors combined. This surprising finding suggests that something as simple as daily time outdoors in natural light may play a meaningful role in protecting brain health as people age. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 21, 2026
Researchers found that lecanemab, a newer drug approved for Alzheimer's disease, can cause a side effect called ARIA — which stands for abnormal changes in the brain that show up on scans, sometimes causing symptoms like headache or confusion. In real-world use outside of carefully controlled studies, about 15 out of every 100 patients experienced some form of ARIA, with higher rates in people who carry a gene variant called APOE ε4 (a genetic factor that raises Alzheimer's risk) or who had small prior bleeds in the brain. This matters because it helps doctors and patients better understand what to watch for when using this treatment in everyday clinical settings — not just in ideal study conditions. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should know about how well lecanemab actually works for Alzheimer's disease outside of research studies, since most of what we know comes from controlled trials.
What's New
ScienceDaily · October 20, 2026
Scientists found that blocking certain immune cells in the brain — cells that were contributing to damage — helped protect brain tissue in mice with Alzheimer's-related changes. Even without clearing out the harmful buildup of a protein called tau (which is linked to Alzheimer's disease), the mice preserved significantly more tissue in the memory areas of the brain and showed better memory. This is an exciting early finding because it suggests there may be a new way to protect the brain that works differently from current approaches — but this is early research and hasn't yet changed treatment guidelines.
Lifestyle
ScienceDaily · October 19, 2026
A press release highlights new research suggesting that walking as few as 3,000 steps a day — roughly 1.5 miles — may help slow certain brain changes linked to Alzheimer's disease in people already showing early signs of it. Researchers found that more active people had less buildup of a harmful protein in the brain called tau (which is associated with Alzheimer's) and experienced nearly half the mental and daily-functioning decline compared to less active people. The benefits appeared strongest at 5,000 to 7,500 steps a day, meaning the commonly cited goal of 10,000 steps may not be necessary to see an effect.
What's New
ScienceDaily · October 19, 2026
A medical press release describes an interesting discovery about Alzheimer's disease and sleep. Scientists found that certain immune cells in the brain become overactive in Alzheimer's and may be a key reason people with the condition often struggle to sleep — and when researchers removed these cells in mice, the animals gained back more than two hours of sleep per day. This matters because sleep problems are very common and distressing for people with Alzheimer's, and finding a new way to address them — one that doesn't rely on clearing the protein build-up typically associated with the disease — could open up new treatment possibilities.
What's New
PubMed · October 19, 2026
Researchers found that people who ate more choline — a nutrient found in eggs, meat, and beans — were about 26% less likely to develop Alzheimer's disease compared to those who ate less of it. Choline helps the brain produce a chemical called acetylcholine, which plays an important role in memory and thinking. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 14, 2026
Researchers found that a new experimental pill called VG-3927 may help the brain's immune cells — called microglia — work better in Alzheimer's disease by activating a protein called TREM2, which helps these cells clear out harmful buildup in the brain. In early lab and animal studies, the drug reduced signs of brain inflammation and nerve damage, and in a small early human trial it appeared safe and reached the brain effectively. This is early research and hasn't yet changed treatment guidelines.
Medications
JAMA · October 13, 2026
Researchers found that the FDA approved two new blood tests that can detect Alzheimer's disease in adults who are showing signs of cognitive symptoms — meaning things like memory problems or confusion — including one test that can be used for people as young as 40 years old. These tests offer a new way to identify Alzheimer's through a simple blood draw, rather than relying only on more involved procedures like brain scans. This represents a new option in how Alzheimer's disease can be detected.
Ask your doctor: Ask the doctor whether the patient should consider getting one of these new blood tests for Alzheimer disease that the FDA just approved, especially since they can be used to check for the disease even in people as young as 40 years old.
What's New
PubMed · October 6, 2026
Researchers found that a brain imaging test called an amyloid PET scan — which looks for a sticky protein buildup linked to Alzheimer's disease — can be measured more consistently using a standardized scoring system, and this study helped identify clearer cutoff scores to tell apart people who likely have that buildup from those who don't. This matters because more reliable scoring could help doctors make better decisions about who might benefit from newer Alzheimer's treatments that target this protein. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · October 6, 2026
Researchers found that certain risk factors for Alzheimer's disease and dementia may actually be modifiable — meaning they are things people can potentially change or manage, rather than factors set in stone like genetics or age. This is exciting because it suggests that some everyday habits or health conditions might play a role in whether or not a person develops dementia later in life, giving researchers new directions to explore for prevention. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · October 6, 2026
Researchers found that a special brain scan called an amyloid PET scan — which detects sticky protein clumps called amyloid plaques, a hallmark of Alzheimer's disease — has become a valuable tool for identifying the disease earlier and helping doctors decide who might benefit from newer treatments that target those plaques. The scan helps confirm whether these plaques are actually present in the brain before treatment begins, and can also help track whether a treatment is working. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 5, 2026
Researchers found that a therapy called electroacupuncture — which uses tiny electrical pulses through acupuncture needles — may help calm a specific type of brain inflammation that is thought to play a role in memory decline and Alzheimer's disease. The inflammation involves an overactive process in brain cells that, when left unchecked, can gradually damage the part of the brain responsible for memory and thinking. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 2, 2026
Researchers found that a common side effect of newer Alzheimer's treatments — called brain imaging abnormalities, which are unusual changes that show up on brain scans — occurred in a notable portion of patients receiving antibody-based therapies targeting amyloid, a protein that builds up in the brains of people with Alzheimer's disease. Most of these abnormalities were mild and caused no obvious symptoms, but people who carry a gene variant called ApoE4 (which is already known to raise Alzheimer's risk) were significantly more likely to experience these side effects and to have more serious cases. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that experimental treatments targeting a harmful protein called tau — which builds up in the brains of people with Alzheimer's disease and is strongly linked to memory and thinking decline — were often able to affect that protein in measurable ways, but those biological changes didn't reliably lead to patients actually feeling or functioning better. Scientists looked at 11 clinical trials testing different approaches, including laboratory-made antibodies and vaccines designed to attack tau, and found a frustrating gap between what the treatments did in the body and whether people with Alzheimer's experienced real benefit. This matters because tau has long been seen as a promising target for slowing the disease, so understanding why these treatments aren't working as hoped could help researchers find better approaches in the future. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that people with a specific high-risk gene variant for Alzheimer's disease (called APOE4/4) who took an experimental oral drug called valiltramiprosate showed encouraging changes in certain proteins in their blood — proteins that scientists use to track brain cell damage and the buildup of harmful clumps thought to drive Alzheimer's. The study also found that people in the earlier stages of the disease (those with mild memory and thinking problems, but not yet full dementia) seemed to benefit more, showing improvements in thinking, daily functioning, and brain scans. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a drug called donanemab appeared to slow the progression of early Alzheimer's disease in people who qualified for it under European approval standards — specifically, those without certain brain bleeding risk factors or uncontrolled high blood pressure. Compared to people who received a placebo (a dummy treatment with no active medicine), those who took donanemab had about a 40% lower chance of their disease advancing to the next stage over roughly a year and a half. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that older adults with early signs of cognitive impairment who took a daily probiotic supplement for six months showed lower blood levels of a protein called tau — a marker linked to Alzheimer's disease — compared to those who took a placebo (a dummy pill). People in the probiotic group also did better on tests measuring memory and the ability to copy and recall shapes and drawings, which are skills that Alzheimer's disease can affect early on. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a specific protein in the blood called p-tau217 — a marker that signals Alzheimer's-related changes in the brain — was better at detecting most stages of Alzheimer's disease compared to other similar proteins being tested. However, it was less reliable at catching the disease in its very earliest stages, before memory or thinking problems become noticeable. This matters because a more accurate blood test could one day help doctors identify Alzheimer's sooner and more easily, without needing more invasive brain scans or spinal fluid tests. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a self-administered digital cognitive test called BraincheX was able to correctly identify most people with early Alzheimer's disease in a small study, performing comparably to a traditional pen-and-paper memory test given by a clinician. This matters because a reliable digital test could make it easier for people to get screened for Alzheimer's from home or in settings where specialist appointments aren't easy to access. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study found that using gentle, non-invasive electrical or magnetic pulses applied to the outside of the head may help improve thinking, memory, language, and daily functioning in people with Alzheimer's disease. One specific technique — repetitive transcranial magnetic stimulation, or rTMS, which uses magnetic pulses near the scalp to gently stimulate brain activity — showed the strongest and most consistent results across the most reliable studies. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · September 28, 2026
Scientists discovered that certain immune cells — the body's defense fighters — may actually be triggered outside the brain, in small glands called lymph nodes, before traveling into the brain and causing damage linked to Alzheimer's disease. In mice, blocking this pathway significantly reduced brain damage and helped preserve memory and thinking abilities. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.